Paradigm Biocapital Advisors »

United Therapeutics Corporation shares owned by Paradigm Biocapital Advisors

Quarter-by-quarter ownership of United Therapeutics Corporation (UTHR) shares owned by Paradigm Biocapital Advisors from 13F filings

Historical chart of Paradigm Biocapital Advisors investment in United Therapeutics Corporation

Tip: Access up to 7 years of quarterly data

All positions including United Therapeutics Corporation held by Paradigm Biocapital Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in United Therapeutics Corporation by Paradigm Biocapital Advisors

Quarter filed Position value Share count Share price at filing
2023-09-30 $69M 307k 225.87
2023-06-30 $53M 238k 220.75
2023-03-31 $48M 212k 223.96
2022-12-31 $41M 149k 278.09
2022-09-30 $29M 141k 209.38
2022-06-30 $38M 163k 235.64
2022-03-31 $14M 76k 179.41

More positions owned by Paradigm Biocapital Advisors

Nuvalent Inc-a (NUVL)
Merus N V Call Option (MRUS)
Arcellx Common Stock (ACLX)
Revolution Medicines (RVMD)
Tarsus Pharmaceuticals (TARS)
Vaxcyte (PCVX)
Abivax Sa Sponsored Ads (ABVX)
Genmab A/s Sponsored Ads (GMAB)
Agios Pharmaceuticals Call Option (AGIO)
Crinetics Pharmaceuticals In (CRNX)
Spdr Series Trust S&p Biotech Put Option (XBI)
Edgewise Therapeutics (EWTX)
Cidara Therapeutics Com New (CDTX)
Urogen Pharma (URGN)
Scholar Rock Hldg Corp (SRRK)

View all positions for Paradigm Biocapital Advisors

Top funds holding United Therapeutics Corporation

BlackRock
Vanguard Group
venBio Select Advisor
Renaissance Technologies
State Street Corporation
Wellington Management Company
Susquehanna International
Geode Capital Management
AQR Capital Management
Darwin Global Management
LSV Asset Management
Assetmark
Invesco
Caption Management
Dimensional Fund Advisors

View all funds holding United Therapeutics Corporation